Navigation Links
St. Jude Study Finds Treatment With New Drug Might Make Tumor Cells More Sensitive to Therapy
Date:9/16/2008

Study shows treatment with a newly discovered drug could be useful in sensitizing tumor cells to therapeutic irradiation and potentially some chemotherapies

MEMPHIS, Tenn., Sept. 16 /PRNewswire-USNewswire/ -- Scientists at St. Jude Children's Research Hospital have shown that it might be possible to make tumor cells more sensitive to irradiation and some types of chemotherapy by treating them with a drug that cripples their ability to repair DNA damage caused by these therapies.

The St. Jude researchers demonstrated in the laboratory that a molecule called CP466722 rapidly blocks the ATM protein's ability to orchestrate a series of biochemical events that culminate in the repair of DNA damaged by irradiation. The molecule exerted its effect in small quantities, and its effects rapidly ended after it was removed from cells, suggesting that such a treatment in humans would not have significant or long-term side effects, the researchers said.

Results of the study were published in the Sept. 15 issue of the journal Cancer Research.

ATM plays a critical role in repairing a type of DNA damage called double-strand breaks, in which each of the two strands making up this molecule are cut, according to Michael Kastan, M.D., Ph.D., director of the St. Jude Comprehensive Cancer Center. This process protects cells from the potentially lethal or mutation-causing effects of free oxygen radicals and irradiation--both of which routinely threaten them, he added. Kastan is senior author of the report on these findings.

Children lacking the gene for ATM develop ataxia-teleangiectasia, a disease that causes several debilitating problems, such as neurodegeneration, cancer and sensitivity to irradiation that leads to irreparable, double-stranded DNA breaks.

"We found that inhibition of ATM activity with CP466722 produces cellular effects that are identical to those seen in cells that lack ATM," Kastan said. "It's as if we temporarily turn
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
2. New Bisphenol A Study Has Limited Capability to Assess Human Health Effects
3. Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
4. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
5. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
6. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
7. Most Cancer Treatment Studies Arent Published, Study Finds
8. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study
11. What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... the development and commercialization of targeted antiviral therapies, announced ... Annual ROTH Conference, to be held March 8-11, ... James Sapirstein , Chief Executive Officer, ... his live presentation and will be available to participate ...
(Date:3/5/2015)... , March 5, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, announced today that ... top rehabilitation hospitals for spinal cord injury and brain ... trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured ... injury (SCI). The Phase 1/2a trial ...
(Date:3/5/2015)... and VANCOUVER, British Columbia ... BUX FSE: 20B OTCQB: BMKDF) -- The ultimate goal ... assay that is capable of detecting tumors before they ... years, the development of such an assay has been ... academia and industry. Although many breakthrough diagnostics have been ...
Breaking Medicine Technology:ContraVir to Present at 27th Annual ROTH Conference 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4New Cancer Diagnostic Primed to Change the Industry 2New Cancer Diagnostic Primed to Change the Industry 3New Cancer Diagnostic Primed to Change the Industry 4
... Kendle (Nasdaq: KNDL ), a leading, global full-service clinical research organization, today ... on June 23, 2010 , at the InterContinental Hotel in Boston . ... Kendle,s formal presentation will be given by Chairman ... Time . , , , ...
... June 17 Brainlab AG today announced that it ... business unit of the Toshiba Group, to integrate its Aquilion™ LB ... operating room (OR). , , ... Stephan Holl , Chief Operating Officer, Brainlab, indicated that ...
Cached Medicine Technology:Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference 2Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite 2Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite 3
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 Shania Twain ... in more than a decade. She has hinted that this ... to miss seeing her perform one last time. She has ... and this beloved country sweetheart has millions of loyal fans around ... throughout her native country, Canada, and on June 30th she will ...
(Date:3/5/2015)... 2015 This week, 60 ... low-cost laminate flooring products, initiating widespread concern from ... building materials made primarily from bamboo, stands behind ... their flooring products for volatile organic compounds (VOCs) ... International (BMH). Results from formaldehyde emissions testing ...
(Date:3/5/2015)... A Bakersfield, Calif. state court jury returned ... awarding the plaintiff Coleen M. Perry a total of $5.7 ... TVT-Abbrevo pelvic mesh sling device, manufactured by Ethicon, Inc., a ... a partner at Wagstaff & Cartmell in Kansas ... along with Rich Freese and Tim Goss of Freese ...
(Date:3/5/2015)... 05, 2015 AxoGen, Inc. (NASDAQ: ... the peripheral nerve repair market, reported record revenue of ... 2014 compared to $2.98 million in the year-ago fourth ... strategies. , “Our strong fourth quarter revenue growth ... repair products which is driving increased surgeon adoption of ...
(Date:3/5/2015)... March 05, 2015 Risperdal lawsuits ... a Pennsylvania mass tort litigation currently underway in ... jury has begun hearing testimony in the proceeding’s ... antipsychotic medication can cause gynecomastia, or male breast ... question was filed on behalf of a plaintiff ...
Breaking Medicine News(10 mins):Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3
... CEO, Will Continue Serving as Chairman of the Board, ... Bulletin Board: MLSS), the recognized leader in,advanced injection technologies, ... Martin, Chief Executive Officer of the Company,s,medical division, as ... of its Board,of Directors, effective January 1, 2008. As ...
... Detection and treatment of tumours, diseased blood vessels and ... an innovative imaging system being developed that uses both ... extremely short pulses of low-energy laser light to stimulate ... area being examined. These waves are then converted into ...
... Amsterdam, December 12, 2007 Elsevier, a leading ... today announced that 45 French-language medical journals from ... January 3, 2008. , The titles, including Feuillets ... Mdicale, represent a wide range of high-quality journals ...
... by 81 percent of Michigan adults, DETROIT, Dec. ... of reform measures proposed in the Michigan Legislature,that would ... increases and set standard rating practices for all insurers ... made public today,by Blue Cross Blue Shield of Michigan., ...
... TITUSVILLE, N.J., Dec. 12 INVEGA(TM) (paliperidone),Extended-Release ... a one-year open-label extension (OLE) study, according ... symptom scores improved or,were stable, on average, ... was designed to evaluate the long-term safety ...
... it. Hair Fairies - The Head Lice, Helpers - is here to ... ... No two words in the English language,can stop every parent in ... other kid-centric services are often,sent into crisis mode when an outbreak occurs, ...
Cached Medicine News:Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 2Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 3Health News:Light and sound -- the way forward for better medical imaging 2Health News:ScienceDirect to host French-language journals from Elsevier Masson 2Health News:Overwhelming Majority of Michigan Residents Favors Individual Health Insurance Market Reforms Supported by Blue Cross Blue Shield of Michigan 2Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 2Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 4Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 5Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 6Health News:Head Lice Removal Service Opens in Chicago 2Health News:Head Lice Removal Service Opens in Chicago 3
... fixed-volume, adjustable-volume, and multichannel models as ... pro Pipette. Designed with a separate ... have earned a worldwide reputation for ... original Eppendorf pipette tips, they provide ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Research Family includes fixed-volume, adjustable-volume, and ... electronic Eppendorf Research pro Pipette. Designed ... compact, high-performance pipettes have earned a ... for use with original Eppendorf pipette ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: